Oncology drug developer Vivace Therapeutics revealed a $15m series A round and a $25m series B, both backed by WuXi Healthcare Ventures, as it emerged from stealth.

Northwestern University spinout Edge Surgical has raised $1.4m in seed funding.

Immune-Onc has licensed research from University of Texas, Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center.

MIP Diagnostics has received additional cash from Mercia Fund Management, which has backed the Leicester spinout since 2015.

The genetic disease treatment developer boosted its overall funding to more than $35m, with LabCorp and corporate venturing unit Spectrum Health Ventures investing.

Johnson & Johnson and Mayo Clinic both invested in DayTwo, the developer of a microbiome health management app, with the latter set to expand its research partnership with the startup.

Samsung and Medtronic returned to back a $35m round for diabetes patient monitoring technology developer Glooko that included Insulet and Mayo Clinic.

The cancer drug conjugate developer floated in the middle of its range, in an offering that provided exits to Takeda subsidiary Millennium Pharmaceuticals and Pfizer.

The spinout of Leiden University Medical Center is working on a treatment that prevents acute bleeding in patients taking medication for thrombosis.